Benzodiazepine, psychotropic medication, and dementia: A population-based cohort study

详细信息    查看全文

• 作者：Dalia Shash^a ; ^b ; ¹ ; Tobias Kurth^a ; ^b ; ¹ ; Marion Bertrand^a ; Carole Dufouil^a ; ^b ; Pascale Barberger-Gateau^b ; ^c ; Claudine Berr^d ; Karen Ritchie^d ; Jean-Francois Dartigues^b ; ^c ; Bernard B&eacute ; gaud^b ; ^e ; Annick Alp&eacute ; rovitch^a ; ^b ; Christophe Tzourio^a ; ^b ; ^{christophe.tzourio@u-bordeaux.fr" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Cohort studies ; Alzheimer's disease ; Dementia ; Benzodiazepine ; Psychotropic medication
• 刊名：Alzheimer's & Dementia
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：12
• 期：5
• 页码：604-613
• 全文大小：807 K

文摘

Benzodiazepine use has been associated with increased risk of dementia. However, it remains unclear whether the risk relates to short or long half-life benzodiazepines and whether it extends to other psychotropic drugs.

Methods

Prospective cohort study among 8240 individuals ≥65, interviewed on medication use. Incident dementia confirmed by an end point committee after a multistep procedure.

Results

During a mean of 8 years of follow-up, 830 incident dementia cases were observed. Users of benzodiazepines at baseline had a 10% increased risk of dementia (adjusted hazard ratio [HR], 1.10; 95% confidence interval, 0.90–1.34). However, long half-life (>20 hours) benzodiazepine users had a marked increased risk of dementia (HR = 1.62; 1.11–2.37) compared with short half-life users (HR = 1.05; 0.85–1.30). Users of psychotropics had an increased risk of dementia (HR = 1.47; 1.16–1.86).

Discussion

Results of this large, prospective study show increased risk of dementia for long half-life benzodiazepine and psychotropic use.